Le Lézard
Classified in: Health
Subjects: MAV, NTA, CFG, DEI

Media Advisory - Prime Minister's itinerary for Saturday, September 30, 2023


OTTAWA, ON, Sept. 29, 2023 /CNW/ -

Note: All times local

Northern Saskatchewan, Saskatchewan



11:00 a.m. 

The Prime Minister will mark the third National Day for Truth and Reconciliation by participating in an awareness walk and attending local community events with community members, Survivors, and leaders.




Note for media:


  • Pooled coverage 

This document is also available at https://pm.gc.ca

SOURCE Prime Minister's Office


These press releases may also interest you

8 mai 2024
Tri-Tech expands emergency medical offering with the strategic acquisition of SAM Medical
Tri-Tech Forensics, Inc. (Tri-Tech), a leading provider of tactical emergency medical solutions and human identification kits, is pleased to announce the acquisition of SAM® Medical (SAM Medical), a globally renowned provider of innovative medical...

8 mai 2024
Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2  The...

8 mai 2024
Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene...

8 mai 2024
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings, Inc. ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the...

8 mai 2024
Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

8 mai 2024
NCPDP Announces Highlights from its 2024 Annual Conference, "Innovation Starts Here"
NCPDP announced today highlights from its 2024 Annual Technology & Business Conference, Innovation Starts Here. "NCPDP's standards and guidance are inherently innovative, and the work we continue to do will expand interoperability to support the...

More news about Health...


News published on and distributed by: